Source: Eur Respir J 2016; 48: 1800-1802
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Richard van Altena, Onno W. Akkerman, Jan-Willem C. Alffenaar, Huib A.M. Kerstjens, Cecile Magis-Escurra, Martin J. Boeree, Dick van Soolingen, Wiel C.M. de Lange, Mathieu S. Bolhuis, Wouter Hoefsloot, Gerard de Vries, Tjip S. van der Werf. Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly. Eur Respir J 2016; 48: 1800-1802

Member's Comments

No comment yet.

Related content which might interest you: Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity? Source: Eur Respir J, 49 (5) 1700738; 10.1183/13993003.00738-2017 Year: 2017 Good news about a bad subject: scientific evidence to help defeat multidrug/extensively drug-resistant tuberculosis Source: Eur Respir J 2014; 44: 5-7 Year: 2014 Failing a re-treatment regimen does not predict MDR/XDR tuberculosis: is “blind” treatment dangerous? Source: Eur Respir J 2011; 37: 1283-1285 Year: 2011 Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis? Source: Eur Respir J, 55 (2) 1901908; 10.1183/13993003.01908-2019 Year: 2020 Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience Source: Eur Respir J 2016; 47: 333-336 Year: 2016 Investing in a novel shorter treatment regimen for multidrug-resistant tuberculosis: to be repeated Source: Eur Respir J , 49 (3) 1700081; DOI: 10.1183/13993003.00081-2017 Year: 2017 Long term treatment out come in multi drug resistant tuberculosis Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis Year: 2010 M. tuberculosis W-strain: MDR or no? Source: Eur Respir J 2003; 22: Suppl. 45, 555s Year: 2003 Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Source: Eur Respir J 2008; 31: 904-905 Year: 2008 Antibiotics in acute exacerbations of COPD: the good, the bad and the ugly Source: Eur Respir J 2012; 40: 1-3 Year: 2012 Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India Source: Eur Respir J 2012; 39: 956-962 Year: 2012 Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis Source: Eur Respir J 2016; 48: 1503-1507 Year: 2016 TB "cross-border" - a new challenge in tuberculosis management Source: Virtual Congress 2020 – Tuberculosis and society Year: 2020 Mycobacterium tuberculosis, how long did you walk? Source: Annual Congress 2013 –Tuberculosis: clinical epidemiology and public health Year: 2013 Shorter treatment duration for selected patients with multidrug-resistant tuberculosis Source: Eur Respir J 2011; 37: 227-230 Year: 2011 Long term treatment outcome in multi drug resistant tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 The continued hunt for the elusive standard short regimen for treatment of multidrug-resistant tuberculosis Source: Eur Respir J, 55 (3) 2000224; 10.1183/13993003.00224-2020 Year: 2020 New short regimens for latent tuberculosis treatment: safety first! Source: Eur Respir J, 52 (6) 1802180; 10.1183/13993003.02180-2018 Year: 2018 Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis? Source: Eur Respir J 2016; 48: 582-585 Year: 2016 What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis? Source: Eur Respir J 2009; 34: 1492-1494 Year: 2009